Don E. Ray was named Chief Financial Officer of Regenerex Pharma, Inc. As of November 6, 2026, Regenerex Pharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 6, 2026, naming 1 appointment (Form 8-K, May 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Regenerex Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Regenerex Pharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Regenerex Pharma, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-06 | In | Chief Financial Officer | 8-K, 2026-05-06 |
Selling to them or working with them? See who runs Regenerex Pharma, Inc. now and the warning signs.
Free to see. No signup.
Watch Regenerex Pharma, Inc.
Get an email when Regenerex Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Regenerex Pharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Regenerex Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Regenerex Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Regenerex Pharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Don E. Ray, appointed (filed 2026-05-06).
New leaders reset buying decisions — get the Full Report on Regenerex Pharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Regenerex Pharma, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Regenerex Pharma, Inc.Every change, in the filing's words
Appointed: Don E. Ray, Chief Financial Officer
In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.
- - Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Mr. Kenneth Perry Chief Financial Officer was placed on administrative suspension with pay effective March 31, 2026.
- Following the Committee's review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry's employment for Cause, with notice of such termination delivered on May 2, 2026.
- On April 27, 2026 the Board of Directors (the "Board") of (the "Company"), acting upon the recommendation of its Governance and Nominating Committee (the "Committee"), determined that the conduct of the Company's Chief Financial Officer, Kenneth Perry, constituted a material and continuing breach of his Employment Agreement and satisfied the definition of "Cause" as set forth therein.
- The Committee, which is comprised of three independent advisors, conducted a comprehensive review of relevant materials, including audit-related findings, Board records, and documented communications.
- Upon completion of its review, the Committee submitted its findings and formal recommendation to the independent members of the Board.
- A meeting of the independent members of the Board was held on April 27, 2026, at which two of the three directors were present.
Tools for this story
Each opens in a new tab, filled in for Regenerex Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.